Medpace Holdings, Inc.

Medpace Holdings, Inc.'s next confirmed earnings release is scheduled for February 15, 2027.

As of June 30, 2026, Medpace Holdings, Inc. has 27.91M shares outstanding.

As of June 30, 2026, Medpace Holdings, Inc. maintains a current ratio of 0.73, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Medpace Holdings, Inc. posted a return on equity (ROE) of 162.15, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 112.48 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 27.09, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 115.48, useful for judging operating efficiency across full business cycles. The company generates approximately 397,605.99 in revenue per employee across its workforce of 6,125.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Medpace Holdings, Inc. recorded 94.03M in income tax expense. That works out to an effective tax rate of 17.94, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 524.24M, leaving 430.21M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Over the twelve months ended June 30, 2026, Medpace Holdings, Inc. generated 2.44B in revenue and converted that into 430.21M in net income, yielding earnings per share of 14.93. EBITDA reached 534.98M, while operating income came in at 510.65M.

As of June 30, 2026, Medpace Holdings, Inc. holds 440.00M in cash and equivalents against 105.12M in total debt, resulting in a net debt position of -440.00M. Total book value stands at 379.76M, with working capital of -337.12M providing operational flexibility.

Medpace Holdings, Inc. produced 658.80M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -3.97M in capital expenditures, free cash flow totaled 654.83M - equivalent to 23.17 per share.

Over the twelve months ended June 30, 2026, Medpace Holdings, Inc. posted a gross margin of 28.76, reflecting its pricing power and cost economics. The operating margin of 20.97 and net profit margin of 17.67 provide insight into operational efficiency.